Winship Cancer Institute
Emory University
Atlanta, GA
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Prior BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
EXCALIBER RRMM
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Learn more- CELMoD
- Randomization
- Phase 3
Accepting patients
KarMMa-2
Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- High Risk
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
Alnuctamab
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 1
- Has results
5 hidden based on your filters. Show All
Filters
Save & Share
Diagnosis
Treatment History
Prior BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Advanced Filters
Classifications
Filter results based on treatment classifications/type.